Insulin × hypoglycaemia

TrialDiabetes care2023

A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA1c ≥9-15%: DUAL HIGH Trial.

Rodolfo J Galindo et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 145 people · 2023

Not counted

Probably lowered hypoglycaemia

−61%−81% to −22%

Bigger than 9 in 10 on the map

As reported

OR 0.39, 95% CI 0.19–0.78

One number in the abstract

the abstract, start to end

(26% vs. 48%, P = 0.008; odds ratio 0.39, 95% CI 0.19, 0.78), and less

← favours treatmentfavours comparator →
could be chance
Hypoglycaemia
OR 0.390.19–0.78
InsulinHypoglycaemia
1 / 3

10 papers cite it

2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 37459574